In the cost of care of rheumatoid arthritis and ankylosing spondylitis patients in tertiary care rheumatology units in Turkey

Basit Öğe Kaydı
dc.authorid0000-0001-6625-1652
dc.authorid0000-0002-5723-5965
dc.authorid0000-0002-3443-3117
dc.authorid0000-0003-1710-7018
dc.contributor.authorMalhan, S.
dc.contributor.authorPay, S.
dc.contributor.authorAtaman, S.
dc.contributor.authorDalkilic, E.
dc.contributor.authorDinc, A.
dc.contributor.authorErken, E.
dc.contributor.authorSoy, Mehmet
dc.date.accessioned2024-09-25T20:01:32Z
dc.date.available2024-09-25T20:01:32Z
dc.date.issued2011
dc.departmentBAİBÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü en_US
dc.description.abstractTo determine the direct and indirect costs due to rheumatoid arthritis (RA) and ankylosing spondylitis (AS) patients in Turkey. Methods An expert panel was convened to estimate the direct and indirect costs of care of patients with RA and AS in Turkey. The panel was composed of 22 experts chosen from all national tertiary care rheumatology units (n=53). To calculate direct costs, the medical management of RA and AS patients was estimated using “cost-of-illness” methodology. To measure indirect costs, the number of days of sick leave, the extent of disability, and the levels of early retirement and early death were also evaluated. Lost productivity costs were calculated using the “human capital approach”, based on the minimum wage. Results The total annual direct costs were 2,917.03 Euros per RA patient and 3,565.9 Euros for each AS patient. The direct costs were thus substantial, but the indirect costs were much higher because of extensive morbidity and mortality rates. The total annual indirect costs were 7,058.99 Euros per RA patient and 6,989.81 for each AS patient. Thus, the total cost for each RA patient was 9,976.01 Euros and that for an AS patient 10,555.72 Euros, in Turkey. Conclusion From the societal perspective, both RA and AS have become burden in Turkey. The cost of lost productivity is higher than the medical cost. Another important conclusion is that indirect costs constitute 70% and 66% of total costs in patients with RA and AS, respectively.
dc.identifier.doi10.1016/j.jval.2011.08.410
dc.identifier.endpageA306en_US
dc.identifier.issn1098-3015
dc.identifier.issue7en_US
dc.identifier.startpageA306en_US
dc.identifier.urihttps://doi.org/10.1016/j.jval.2011.08.410
dc.identifier.urihttps://hdl.handle.net/20.500.12491/14188
dc.identifier.volume14en_US
dc.identifier.wosWOS:000299107100384en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.institutionauthorSoy, Mehmet
dc.institutionauthorid0000-0003-1710-7018
dc.language.isoenen_US
dc.publisherElsevier Science Incen_US
dc.relation.ispartofValue in Healthen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmzYK_20240925en_US
dc.subjectRheumatoid Arthritis
dc.subjectAnkylosing Spondylitis
dc.subjectCost
dc.subjectTurkey
dc.subjectImportant Conclusion
dc.subjectCost-of-Illness
dc.titleIn the cost of care of rheumatoid arthritis and ankylosing spondylitis patients in tertiary care rheumatology units in Turkeyen_US
dc.typeConference Objecten_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu